Korean Circulation Journal

The Korean Society of Cardiology (대한심장학회)
권호 표지
DOI QR코드

DOI QR Code

Effect of Hyperkalemia and Hemolysis Caused by Hyperacute Rejection on Cardiac Function in Pig to Human Ex Vivo Xenogeneic Cardiac Perfusion Model

  • Kim, Jun-Seok (Department of Thoracic and Cardiovascular Surgery, School of Medicine, Konkuk University) ;
  • Lee, Hak-Mo (Xenotransplantation Research Center, Seoul National University Hospital) ;
  • Oh, Byoung-Chol (Xenotransplantation Research Center, Seoul National University Hospital) ;
  • Lim, Hong-Gook (Xenotransplantation Research Center, Seoul National University Hospital) ;
  • Lee, Jeong-Ryul (Xenotransplantation Research Center, Seoul National University Hospital)
  • Published : 2011.03.30
⟨ Previous Next ⟩

Abstract

Background and Objectives: Hyperacute rejection (HAR) is a major obstacle to successful xenotransplantation of vascularized organs. This study was conducted to observe the effect of hemolysis of perfused human whole blood on pig heart function, and determine the major risk factors for preservation of xenoperfused cardiac function using ex-vivo pig to human xenogeneic cardiac perfusion model. Materials and Methods: Harvested pig hearts were perfused with normal human whole blood (group 1), two different types of pre-treated human whole blood (group 2: immunoglobulins were depleted by plasmapheresis, group 3: pre-treated with plasmapheresis, GAS914, cobra venom factor (CVF) and steroid), and normal porcine wh-ole blood as control (group 4) for 3 hours. Results: Duration of heart beat was significantly prolonged in group 2 and group 3. Histological examination showed widespread HAR features but was gradually delayed in groups 2 and 3 compared to group 1. The absolute levels of serum creatine kinase-MB and Troponin I increased gradually, and was lower in group 3. Serum hemo-globin levels were rapidly increased in groups 3 and 4, compared to group 1. Extracellular potassium level increased sharply from the beginning of blood perfusion in groups 1, 2 and 3, compared to group 4. Conclusion: Pretreatment of human whole blood, including immunoglobulin depletion, CVF and steroid reduced and delayed the destruction of pig myocardium by HAR. However, the increased extracellular potassium levels in groups 1, 2 and 3 reflected that these treatments could not prohibit myocardial injury by HAR.

Keywords

References

  1. Lee JR, Kim HK, Kim JS, et al. Effect of antibody titer on xenograft survival in pig-to-dog heterotropic cardiac xenotransplantation. Korean J Thorac Cardiovasc Surg 2004;37:391-400.
  2. Sachs DH. The pig as a xenograft donor. Pathol Biol (Paris) 1994;42: 217-9.
  3. Sykes M, Lee LA, Sachs DH. Xenograft tolerance. Immunol Rev 1994;141:245-76. https://doi.org/10.1111/j.1600-065X.1994.tb00880.x
  4. Tonomura N, Shimizu A, Wang S, et al. Pig islet xenograft rejection in a mouse model with an established human immune system. Xenotransplantation 2008;15:129-35. https://doi.org/10.1111/j.1399-3089.2008.00450.x
  5. Rydberg L, Hallberg E, Bjorck S. Studies on the removal of anti-pig in the human by plasmapheresis/immunoadsorption. Xenotransplantation 1995;2:253-9. https://doi.org/10.1111/j.1399-3089.1995.tb00106.x
  6. Leventhal JR, John R, Fryer JP, et al. Removal of baboon and human antiporcine IgG and IgM natural antibodies by immunoadsorption: results of in vitro and in vivo studies. Transplantation 1995;59:294-300. https://doi.org/10.1097/00007890-199501000-00024
  7. Shimizu A, Hisashi Y, Kuwaki K, et al. Thrombotic microangiopathy associated with humoral rejection of cardiac xenografts from alpha 1, 3-galactosyltransferase gene-knockout pigs in baboons. Am J Pathol 2008;172:1471-81. https://doi.org/10.2353/ajpath.2008.070672
  8. Kimikawa M, Agishi T, Teraoka S, Suga H, Hayasaka Y, Ota K. Prolongation of cardiac xenograft survival by double filtration plasmapheresis and ex vivo xenoantibody adsorption. Transplant Proc 1992; 24:447.
  9. Nishitai R, Ikai I, Matsuo K, et al. Influence of extracorporeal porcine liver perfusion on nonhuman primates: minimizing hemolysis improves subsequent survival. Liver Transpl 2001;7:615-22. https://doi.org/10.1053/jlts.2001.25362
  10. Macchiarini P, Mazmanian GM, Oriol R, et al. Ex vivo lung model of pig-to-human hyperacute rejection. J Thorac Cardiovasc Surg 1997; 114:315-25. https://doi.org/10.1016/S0022-5223(97)70175-2
  11. Baek SH. The current concept of cell therapy for heart failure. Korean Circ J 2005;35:415-23. https://doi.org/10.4070/kcj.2005.35.6.415
  12. Kroshus TJ, Bolman RM, Dalmasso AP. Selective IgM depletion prolongs organ survival in an ex vivo model of pig-to-human xenotransplantation. Transplantation 1996;62:5-12. https://doi.org/10.1097/00007890-199607150-00002
  13. Katopodis AG, Warner RG, Duthaler RO, et al. Removal of anti-$Gal{\alpha}1$,3Gal xenoantibodies with an injectable polymer. J Clin Invest 2002;110:1869-77. https://doi.org/10.1172/JCI16526
  14. Tanemura M, Yin D, Chong AS, Galili U. Differential immune responses to $\alpha$-gal epitopes on xenografts and allografts: implications for accommodation in xenotransplantation. J Clin Invest 2000;105: 301-10. https://doi.org/10.1172/JCI7358
  15. Brandl U, Michel S, Erhardt M, et al. Administration of GAS914 in an orthotopic pig to baboon heart transplantation model. Xenotransplantation 2005;12:134-41. https://doi.org/10.1111/j.1399-3089.2005.00208.x
  16. Walpen AJ, Mohacsi P, Frey C, Roos A, Daha MR, Rieben R. Activation of complement pathways in xenotransplantation: an in vivo study. Transpl Immunol 2002;9:271-80. https://doi.org/10.1016/S0966-3274(02)00081-3
  17. Kim CH, Zo JH, Seo JD, Lee YW, Brooks E. Evolutional change of vasoactive substances in rat model of chronic heart failure. Korean Circ J 1997;27:767-73. https://doi.org/10.4070/kcj.1997.27.7.767
  18. Kobayashi T, Taniguchi S, Neethling FA, et al. Delayed xenograft rejection of pig-to-baboon cardiac transplants after cobra venom factor therapy. Transplantation 1997;64:1255-61. https://doi.org/10.1097/00007890-199711150-00005
  19. Vogel CW, Fritzinger DC, Hew BE, Thorne M, Bammert H. Recombinant cobra venom factor. Mol Immunol 2004;41:191-9. https://doi.org/10.1016/j.molimm.2004.03.011
  20. Grimm H, Mages P, Lindemann G, et al. Evidence against a pivotal role of preformed antibodies in delayed rejection of a guinea pig-to-rat heart xenograft. J Thorac Cardiovasc Surg 2000;119:477-87. https://doi.org/10.1016/S0022-5223(00)70126-7
  21. Oberholzer J, Yu D, Triponez F, et al. Decomplementation with cobra venom factor prolongs survival of xenografted islets in a rat to mouse model. Immunology 1999;97:173-80. https://doi.org/10.1046/j.1365-2567.1999.00742.x
  22. Fischel RJ, Bolman RM 3rd, Platt JL, Najarian JS, Bach FH, Matas AJ. Removal of IgM antiendothelial antibodies results in prolonged cardiac xenograft survival. Transplant Proc 1990;22:1077-8.
  23. Suga H, Ishida H, Kimikawa M, et al. Prolongation of cardiac xenograft function after reduction of natural antibodies using double filtration plasmapheresis. ASAIO Trans 1991;37:M433-4.
  24. Sato Y, Kimikawa M, Suga H, et al. Prolongation of cardiac xenograft survival by double filtration plasmapheresis and ex vivo immunoadsorption. ASAIO J 1992;38:M673-5. https://doi.org/10.1097/00002480-199207000-00122
  25. Satoh S, Terajima H, Yagi T, et al. Humoral injury in porcine livers perfused with human whole blood. Transplantation 1997;64:1117-23. https://doi.org/10.1097/00007890-199710270-00006
  26. Yeh JH, Chen WH, Chiu HC. Complication of double-filtration plasmapheresis. Transfusion 2004;44:1621-5. https://doi.org/10.1111/j.1537-2995.2004.04154.x
  27. Tambourgi DV, dos Santos MC, Furtado M de F, de Freitas MC, da Silva WD, Kipnis TL. Pro-inflammatory activities in elapsed snake venoms. Br J Pharmacol 1994;112:723-7. https://doi.org/10.1111/j.1476-5381.1994.tb13137.x
  28. Ahn JM, Kim JJ, Song MG, et al. The efficacy and safety of an immunosuppressive regimen including the use of mycophenolate mofetil and an interleukin-2 monoclonal antibody in heart transplant patients. Korean Circ J 2006;36:794-801. https://doi.org/10.4070/kcj.2006.36.12.794